- Vir Biotechnology also partners with National Institute of Allergy and Infectious Diseases (NIAID) to fight coronaviruses
- Vir and Biogen negotiating Clinical Development and Manufacturing Agreement
San Francisco: Vir Biotechnology has on Thursday the 12th announced its intentions to partner up with Biogen INC for development and production of human monoclonal antibodies for the treatment of coronavirus. It has also signed a letter of intent with the latter.
CEO of Vir Biotechnology, George Scangos said, “These exceptional circumstances presented by the threat of COVID-19 require that we work with great urgency in the interest of the public good. Biogen is one of the global leaders in cell line and process development for advanced biologics; tapping into their capabilities will provide us with a U.S. base for supply and manufacture of antibody therapies.”
Numerous monoclonal antibodies that can be used against SARS-CoV-2 have been identified by Vir Biotechnology by studying a patient who had contracted SARS. The company over time has developed 4 such platforms that analyze clinical observations in the naturally occurring immune system processes.
Vir Biotechnology and Biogen Inc also plans to exchange crucial data as well as materials procured until now like antibodies. Individually and in collaboration these two entities will explore various possibilities of developing a vaccine for COVID-19.
Vir Biotechnology has been successful in developing antibodies for viruses like Ebola, influenza A, hepatitis B, malaria etc. The collaboration will also focus on developing antibodies and vaccine on current as well as viruses that will emerge in future.